84494-72-4

Basic information

• Product Name: CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER
• Synonyms: 4,7,10,13,16,19-docosahexaenoicacidethylester;ETHYL CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE;CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER;DHA ETHYL ESTER;cis-4,7,10,13,16,19-Docosahexaenoic acid ethyl ester (stabilized with vitamine E);cis-4,7,10,13,16,19-docosahexaenoic*acid ethyl es;CIS-4,7,10,13,16,19-DOCOSAHEXAENOICACID ETHYL ESTE;CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER (STABILIZED WITH VITAMIN E) 95+%
• CAS NO: 84494-72-4
• Molecular Formula: C24H36O2
• Molecular Weight: 356.54
• Product Categories: Biochemistry;Higher Fatty Acids & Higher Alcohols;Unsaturated Higher Fatty Acid Esters;Ethyl EsterBiochemicals Found in Plants;Esters;Lipids;Polyunsaturated;Unsaturated fatty acids and derivatives;Ethyl Ester
• Mol File: 84494-72-4.mol

Chemical Properties

• Boiling Point: 443.5 °C at 760 mmHg
• Flash Point: 102.1 °C
• Appearance: /
• Density: 0.914 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.4910-1.4960
• Storage Temp.: −20°C
• CAS DataBase Reference: CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER(84494-72-4)
• EPA Substance Registry System: CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER(84494-72-4)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 84494-72-4(Hazardous Substances Data)

Usage

Uses

Used in Nutritional Supplements:
CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER is used as a nutritional supplement for its role in maintaining the health and function of the retina and brain. It is particularly beneficial for individuals who may not be able to obtain sufficient amounts of omega-3 fatty acids through their diet alone.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER is used as an active ingredient in various formulations designed to support cognitive function, brain health, and retinal health. Its presence in these products is aimed at providing the necessary nutrients to support the proper functioning of the brain and eyes.
Used in Nutraceutical Industry:
CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER is also used in the nutraceutical industry for its potential health benefits. It is incorporated into various products such as dietary supplements, functional foods, and beverages that are marketed to promote overall health and well-being.
Used in Cosmetics Industry:
In the cosmetics industry, CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER is used in skincare products for its potential anti-inflammatory and moisturizing properties. It is believed to help maintain the health and appearance of the skin, making it a popular ingredient in various cosmetic formulations.
Used in Research and Development:
CIS-4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER is also used in research and development for its potential therapeutic applications. Scientists and researchers are continually exploring the benefits of this omega-3 fatty acid in various fields, including neuroscience, ophthalmology, and cardiology, to develop new treatments and therapies for various health conditions.

InChI:InChI=1/C24H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26-4-2/h5-6,8-9,11-12,14-15,17-18,20-21H,3-4,7,10,13,16,19,22-23H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-

Upstream product

• 1026237-62-6 (4Z,7Z,10Z)-13-Oxo-trideca-4,7,10-trienoic acid ethyl ester 
• 64-17-5 ethanol 
• 1553-41-9 5,8,11,14,17-eicosapentaenoic acid 
• 6217-54-5 docosahexaenoic acid 
• 122-51-0 orthoformic acid triethyl ester 
• 105-58-8 Diethyl carbonate 
• 98776-99-9 (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl chloride 
• 161794-74-7 (3Z,6Z)-nona-3,6-dienyl p-toluenesulfonate 
• 159145-96-7 Toluene-4-sulfonic acid (3Z,6Z)-8-(2,2-dimethyl-[1,3]dioxolan-4-yl)-octa-3,6-dienyl ester 
• 159145-99-0 Ethyl (Z,Z,Z)-13,14-O-Isopropylidenetetradeca-4,7,10-trienoate 
• 159145-91-2 1-(Tosyloxy)-5-hexen-2-yne 
• 159146-00-6 Ethyl (Z,Z)-13,14-Dihydroxytetradeca-4,7,10-trienoate 
• 159145-92-3 1-(Tetrahydropyranyloxy)dec-9-ene-3,6-diyne 
• 159145-95-6 (Z,Z)-9,10-O-Isopropylidenedeca-3,6-dien-1-ol 

Downstream Products

• 1022976-32-4 (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaen-1-yl 4-methylbenzenesulfonate 
• 78144-19-1 5-[(3Z,6Z,9Z,12Z,15Z)-1-iodooctadeca-3,6,9,12,15-pentaenyl]dihydro-2(3H)-furanone 
• 845673-68-9 5-[(3Z,6Z,9Z,12Z,15Z)-1-hydroxyoctadeca-3,6,9,12,15-pentaenyl]dihydro-2(3H)-furanone 
• 6217-54-5 docosahexaenoic acid 
• 1282618-08-9 (4Z,7Z,10Z,13Z,16Z,19Z)-N-((R)-1-hydroxypropan-2-yl)docosa-4,7,10,13,16,19-hexaenamide 
• 1333067-15-4 (4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoic acid [2-((4Z,7Z,10Z,13Z, 16Z,19Z)docosa-4,7,10,13,16,19-hexaenoylamino)ethyl]amide 
• 140670-40-2 (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 2,3-dihydroxy-propyl ester 
• 1048012-06-1 (4Z,7Z,10Z,13Z,16Z,19Z)-N-(2,3-dihydroxypropyl)docosa-4,7,10,13,16,19-hexaenamide 
• 162758-94-3 N-docosahexaenoylethanolamine 
• 2566-90-7 all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester 
• 121818-29-9 methyl 3-(3-((2Z,5Z,8Z,11Z,14Z)-heptadeca-2,5,8,11,14-pentaen-1-yl)oxiran-2-yl)propanoate 

Relevant articles and documents

GEMCITABINE PRODRUGS

Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.

Proline derivatives incorporating hydrophobic long-chain derived from natural and synthetic fatty acids

The α-hydrophobic long chain-α-amino esters are prepared by α-hydroxylation of a series of fatty acid esters [derived from oleic acid (OA), linoleic acid (LA), arachidonic acid (ARA) and docosahexaenoic acid (DHA)] followed by Mitsunobu reaction and hydrazinolysis of the phthalimide. These amino esters are mixed with aldehydes and electrophilic alkenes to give very good chemical yields and diastereoselectivities of prolinate derivatives incorporating a hydrophobic long chain at the α-position. This multicomponent 1,3-dipolar cycloaddition (1,3-DC) takes place at room temperature. The synthesis of the homologue hydrophobic chain of OA is performed by its oxidation to aldehyde/racemic N-tert-butylsulfinyl imine/Neff reaction. Final 1,3-DC with benzaldehyde and N-methylmaleimide affords homologue prolinate derivative in good yield.

Preparation of n-3 PUFAs ethyl esters by an efficient biocatalyzed solvent-free process

alpha-Linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been subjected to esterification with ethanol in presence of lipase B from Candida antarctica (Novozym 435), in solvent free condition. The use of alcohol donors triethyl orthoformate (TEOF) or diethyl carbonate (DEC) instead of free ethanol, allowed working in irreversible esterification conditions and ALA-, EPA- and DHA-ethyl esters were obtained in quantitative yields.

METHODS OF PREPARING FREE POLYUNSATURATED FATTY ACIDS

Provided herein are methods of making compositions of free fatty acids and alkyl esters of polyunsaturated fatty acids (PUFAs). Also provided are compositions comprising a PUFA selected from a free fatty acid or a ester wherein the PUFA is made according to a method of the invention.

Compositions and methods of omega polyunsaturated fatty acids for the treatment of oral diseases

The invention discloses a novel discovery of anti-microbial activity against oral bacteria, which can be applied for controlling and preventing oral diseases, of omega-3, omega-6, and omega-9 fatty acids, but not limited to omega-3, omega-6, and omega-9 fatty acids; omega-3, omega-6, and omega-9 fatty acid methyl esters, and omega-3, omega-6, omega-9 fatty acid ethyl esters and their application method. The application of this discovery includes the preparation of drugs, dietary supplements, food and daily necessities with oral health care and therapeutic effects.

Process for the preparation of a composition comprising unsaturated compounds

The present invention relates to a process for the preparation of a composition comprising unsaturated compounds, in particular polyunsaturated compounds, which comprises concentrating and purifying the compounds by contact with silicon and/or aluminium derivatives. The process of the invention represents an advantageous substitute of the usual distillation processes, coupled or not to chromatographic processes, and allows to isolate and remove polar byproducts.

LIPASE-CATALYSED ESTERIFICATION OF MARINE OIL

Marine oil compositions which contain EPA and DHA as free acids or hexyl esters are esterified with ethanol in the presence of a lipase catalyst under essentially organic solvent-free conditions and separated by distillation.

New Synthon for the Convergent Construction of Skipped Conjugation Polyenes: Synthesis of Ethyl Docosa-4,7,10,13,16,19-hexaenoate

The preparation and subsequent Wittig reaction of the (Z,Z)-phosphonium salt 4, a useful synthon for the preparation of skipped conjugation polyenes, are reported.Salt 4 is a key intermediate for the synthesis of ethyl docosa-4,7,10,13,16,19-hexaenoate (3